Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia

BACKGROUND: Passive immunization against SARS-CoV-2 limits viral burden and death from COVID-19; however, it poses a theoretical risk of disease exacerbation through antibody-dependent enhancement (ADE). ADE after anti-SARS-CoV2 antibody treatment has not been reported, and therefore the potential r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegazy, Ahmed N., Krönke, Jan, Angermair, Stefan, Schwartz, Stefan, Weidinger, Carl, Keller, Ulrich, Treskatsch, Sascha, Siegmund, Britta, Schneider, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188919/
https://www.ncbi.nlm.nih.gov/pubmed/35692034
http://dx.doi.org/10.1186/s12879-022-07513-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188919/
https://www.ncbi.nlm.nih.gov/pubmed/35692034
http://dx.doi.org/10.1186/s12879-022-07513-0

Ejemplares similares